Concurrent Involved-field Radiotherapy and XELOX Versus XELOX Chemotherapy Alone in Gastric Cancer Patients With Postoperative Locoregional Recurrence

Concurrent involved-field radiotherapy and XELOX showed better responses and overall symptom-control rates compared with XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. A trend of survival benefit from radiochemotherapy was also observed but needs to be further explored.